Evidence for a new pathophysiological mechanism for coronary artery disease regression - Hepatic lipase-mediated changes in LDL density

被引:205
作者
Zambon, A
Hokanson, JE
Brown, BG
Brunzell, JD
机构
[1] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA
[2] Univ Washington, Div Cardiol, Seattle, WA 98195 USA
关键词
stenosis; lipoproteins; lipids; atherosclerosis;
D O I
10.1161/01.CIR.99.15.1959
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Small, dense LDL particles are associated with coronary artery disease (CAD) and predict angiographic changes in response to lipid-lowering therapy. Intensive lipid-lowering therapy in the Familial Atherosclerosis Treatment Study (FATS) resulted in significant improvement in CAD. This study examines the relationship among LDL density, hepatic lipase (HL), and CAD progression, identifying a new biological mechanism for the favorable effects of lipid-altering therapy. Methods and Results-Eighty-eight of the subjects in FATS with documented coronary disease, apolipoprotein B levels greater than or equal to 125 mg/dL, and family history of CAD were selected for this study. They were randomly assigned to receive lovastatin (40 mg/d) and colestipol (30 g/d), niacin (4 g/d) and colestipol, or conventional therapy with placebo alone or with colestipol in those with elevated LDL cholesterol levels. Plasma hepatic lipase (HL), lipoprotein lipase, and LDL density were measured when subjects were and were not receiving lipid-lowering therapy. LDL buoyancy increased with lovastatin-colestipol therapy (7.7%; P<0.01) and niacin-colestipol therapy (10.3%; P<0.01), whereas HL decreased in both groups (-14% [P<0.01] and -17% [P<0.01] with lovastatin-colestipol and niacin-colestipol, respectively). Changes in LDL buoyancy and HL activity were associated with changes in disease severity (P<0.001). In a multivariate analysis, an increase in LDL buoyancy was most strongly associated with CAD regression, accounting for 37% of the variance of change in coronary stenosis (P<0.01), followed by reduction in apolipoprotein B1 (5% of variance; P<0.05). Conclusions-These studies support the hypothesis that therapy-associated changes in HL alter LDL density, which favorably influences CAD progression. This is a new and potentially clinically relevant mechanism linking lipid-altering therapy to CAD improvement.
引用
收藏
页码:1959 / 1964
页数:6
相关论文
共 53 条
[1]   Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans [J].
Anber, V ;
Griffin, BA ;
McConnell, M ;
Packard, CJ ;
Shepherd, J .
ATHEROSCLEROSIS, 1996, 124 (02) :261-271
[2]  
ARMITAGE P, 1971, STATISTICAL METHODS, P314
[3]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
[4]   ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].
AUSTIN, MA ;
KING, MC ;
VRANIZAN, KM ;
KRAUSS, RM .
CIRCULATION, 1990, 82 (02) :495-506
[5]   LARGE BUOYANT LDL-LIKE PARTICLES IN HEPATIC LIPASE DEFICIENCY [J].
AUWERX, JH ;
MARZETTA, CA ;
HOKANSON, JE ;
BRUNZELL, JD .
ARTERIOSCLEROSIS, 1989, 9 (03) :319-325
[6]   DETECTION AND CHARACTERIZATION OF THE HETEROZYGOTE STATE FOR LIPOPROTEIN-LIPASE DEFICIENCY [J].
BABIRAK, SP ;
IVERIUS, PH ;
FUJIMOTO, WY ;
BRUNZELL, JD .
ARTERIOSCLEROSIS, 1989, 9 (03) :326-334
[7]   Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system [J].
Bjornheden, T ;
Babyi, A ;
Bondjers, G ;
Wiklund, O .
ATHEROSCLEROSIS, 1996, 123 (1-2) :43-56
[8]  
BROWN BG, 1993, CIRCULATION, V87, P66
[9]   REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].
BROWN, G ;
ALBERS, JJ ;
FISHER, LD ;
SCHAEFER, SM ;
LIN, JT ;
KAPLAN, C ;
ZHAO, XQ ;
BISSON, BD ;
FITZPATRICK, VF ;
DODGE, HT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298
[10]  
BRUNZELL JD, IN PRESS METABOLIC M